Table 1.
Characteristics of the patients enrolled in the study
| Patient characteristics | N = 271 |
|---|---|
| Age (years) | 57 ± 10† |
| Sex (male/female) | 140/131 |
| Body mass index | 24 ± 3† |
| Liver fibrosis (Stage 1/2/3/4) | 71/82/60/6 |
| Hepatitis activity (Grade 1/2/3) | 164/49/6 |
| rs 8099917 of IL28B (TT/TG/GG) | 198/72/1 |
| rs 738409 of PNPLA3 (CC/CG/GG) | 81/136/54 |
| HCV core amino acids 70 (arginine/glutamine) | 150/91 |
| Alanine aminotransferase (IU/L) | 66 ± 55† |
| Platelet count (10000 /mm3) | 17 ± 6† |
| Alpha fetoprotein (ng/mL) | 11 ± 19† |
| HOMA-IR | 4.2 ± 8.4† |
| Therapeutic outcome (SVR/relapse/NVR) | 126/77/68 |
†: Mean ± standard deviation; PNPLA3, patatin-like phospholipase domain-containing protein 3; HOMA-IR, homeostasis model assessment insulin resistance; SVR, sustained virological response; NVR, null or partial virological response.